Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz3. fázis

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

A legfontosabb adatok

Hol
Arlington, Baltimore, Baton Rouge, Bellaire, Bexley, Boardman, Boston, Bowling Green, Brighton, Chapel Hill, Cincinnati, Clearwater, Cleveland, East Windsor, Fort Gratiot, Fort Smith, Gahanna, Hialeah, Hollywood, Indianapolis, Kew Gardens, Laguna Niguel, Los Angeles, Louisville, Maitland, Margate, Marietta, Marriottsville, Metairie, Miami, Minneapolis, Murfreesboro, New Orleans, New York, Norfolk, North Miami Beach, Oakland, Ocala, Pflugerville, Phoenix, Plano, Portland, Portsmouth, Quincy, Rochester, Rogers, San Antonio, San Diego, Scottsdale, Spokane, St Louis, Tampa, Waterford és West Dundee (Egyesült Államok)Mind a 61 helyszín megnézése
Fázis
3. fázis

Helyszínek itt: Egyesült Államok

  • Arlington, TexasHospital not named in the registryNo longer taking part
  • Baltimore, MarylandHospital not named in the registryNo longer taking part
  • Baton Rouge, LouisianaHospital not named in the registryNo longer taking part
  • Bellaire, TexasHospital not named in the registryNo longer taking part
  • Bellaire, TexasHospital not named in the registryNo longer taking part
  • Bexley, OhioHospital not named in the registryNo longer taking part
  • Bexley, OhioHospital not named in the registryNo longer taking part
  • Boardman, OhioHospital not named in the registryNo longer taking part
  • Boston, MassachusettsHospital not named in the registryNo longer taking part
  • Boston, MassachusettsHospital not named in the registryNo longer taking part
  • Bowling Green, KentuckyHospital not named in the registryNo longer taking part
  • Brighton, MassachusettsHospital not named in the registryNo longer taking part
  • Chapel Hill, North CarolinaHospital not named in the registryNo longer taking part
  • Cincinnati, OhioHospital not named in the registryNo longer taking part
  • Clearwater, FloridaHospital not named in the registryNo longer taking part
  • Cleveland, OhioHospital not named in the registryNo longer taking part
  • East Windsor, New JerseyHospital not named in the registryNo longer taking part
  • Fort Gratiot, MichiganHospital not named in the registryNo longer taking part
  • Fort Smith, ArkansasHospital not named in the registryNo longer taking part
  • Gahanna, OhioHospital not named in the registryNo longer taking part
  • Hialeah, FloridaHospital not named in the registryNo longer taking part
  • Hollywood, FloridaHospital not named in the registryNo longer taking part
  • Hollywood, FloridaHospital not named in the registryNo longer taking part
  • Indianapolis, IndianaHospital not named in the registryNo longer taking part
  • Indianapolis, IndianaHospital not named in the registryNo longer taking part
  • Kew Gardens, New YorkHospital not named in the registryNo longer taking part
  • Laguna Niguel, CaliforniaHospital not named in the registryNo longer taking part
  • Los Angeles, CaliforniaHospital not named in the registryNo longer taking part
  • Louisville, KentuckyHospital not named in the registryNo longer taking part
  • Maitland, FloridaHospital not named in the registryNo longer taking part
  • Margate, FloridaHospital not named in the registryNo longer taking part
  • Marietta, GeorgiaHospital not named in the registryNo longer taking part
  • Marriottsville, MarylandHospital not named in the registryNo longer taking part
  • Metairie, LouisianaHospital not named in the registryNo longer taking part
  • Miami, FloridaHospital not named in the registryNo longer taking part
  • Miami, FloridaHospital not named in the registryNo longer taking part
  • Minneapolis, MinnesotaHospital not named in the registryNo longer taking part
  • Murfreesboro, TennesseeHospital not named in the registryNo longer taking part
  • New Orleans, LouisianaHospital not named in the registryNo longer taking part
  • New YorkHospital not named in the registryNo longer taking part
  • Norfolk, VirginiaHospital not named in the registryNo longer taking part
  • North Miami Beach, FloridaHospital not named in the registryNo longer taking part
  • Oakland, CaliforniaHospital not named in the registryNo longer taking part
  • Ocala, FloridaHospital not named in the registryNo longer taking part
  • Pflugerville, TexasHospital not named in the registryNo longer taking part
  • Phoenix, ArizonaHospital not named in the registryNo longer taking part
  • Plano, TexasHospital not named in the registryNo longer taking part
  • Portland, OregonHospital not named in the registryNo longer taking part
  • Portsmouth, New HampshireHospital not named in the registryNo longer taking part
  • Quincy, MassachusettsHospital not named in the registryNo longer taking part
  • Rochester, New YorkHospital not named in the registryNo longer taking part
  • Rogers, ArkansasHospital not named in the registryNo longer taking part
  • San Antonio, TexasHospital not named in the registryNo longer taking part
  • San Diego, CaliforniaHospital not named in the registryNo longer taking part
  • Scottsdale, ArizonaHospital not named in the registryNo longer taking part
  • Spokane, WashingtonHospital not named in the registryNo longer taking part
  • St Louis, MissouriHospital not named in the registryNo longer taking part
  • Tampa, FloridaHospital not named in the registryNo longer taking part
  • Tampa, FloridaHospital not named in the registryNo longer taking part
  • Waterford, MichiganHospital not named in the registryNo longer taking part
  • West Dundee, IllinoisHospital not named in the registryNo longer taking part

A vizsgálat adatai

Ki végzi
Incyte Corporation
Azonosító
NCT06212999EU 2023-507204-31-00
A regiszteradat frissítve
2026. augusztus 25.
Eredeti leírás
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).A teljes eredeti leírásKevesebb

A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).

Bevonási feltételek: Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302); Agreement to use contraception; Willing and able to comply with the study protocol and procedures; Further inclusion criteria apply.

Kizáró feltételek: Participation in the extension study could expose the participant to an undue safety risk; Women who are pregnant (or who are considering pregnancy) or breastfeeding; Further exclusion criteria apply.

ClinicalTrials.gov NCT06212999 · EU CTIS 2023-507204-31-00